Back
ESC Premium Access

LDL-C treatment patterns and associated outcomes in patients with type 2 diabetes and CVD: insights from TECOS

Session: Poster Session 2 - Cardiovascular risk and its modification
Topic: Lipid-Lowering Agents
Speaker: Professor G. De Ferrari (Turin, IT)
Event: ESC Congress 2018

Congress Presentation

Add to my library

Like

About the speaker

Professor Gaetano Maria De Ferrari

Hospital Molinette of the University Hospital S. Giovanni Battista, Turin (Italy)
18 presentations
0 follower

5 more presentations in this session

Sex-specific analysis on efficacy and safety of statins: a systematic review and quantitative meta-analysis

Speaker: Miss M. Schreuder (Rotterdam, NL)

Access
Abstract
Slides
Like
Thumbnail

Changes in plasma lipid species following pravastatin treatment predict cardiovascular outcomes and represent a measure of the relative risk reduction in secondary prevention

Speaker: Professor P. Meikle (Melbourne, AU)

Access
Abstract
Slides
Like
Thumbnail

Empagliflozin reduces mortality in patients with type 2 diabetes and a history of left ventricular hypertrophy: a sub-analysis of the EMPA-REG OUTCOME trial

Speaker: Professor S. Verma (Toronto, CA)

Access
Abstract
Like
Thumbnail

Reduction in systolic blood pressure with semaglutide treatment is not due to weight loss alone: data from SUSTAIN 1-5

Speaker: Professor S. Bain (Swansea, GB)

Access
Abstract
Slides
Like
Thumbnail

Empagliflozin reduces mortality and hospitalisation for heart failure irrespective of cardiovascular risk score at baseline

Speaker: Doctor D. Fitchett (Toronto, CA)

Access
Abstract
Slides
Like
Thumbnail

Access the full session

Poster Session 2 - Cardiovascular risk and its modification

Speakers: Professor G. De Ferrari, Miss M. Schreuder, Professor P. Meikle, Professor S. Verma, Professor S. Bain...
Access
Like
Thumbnail

About the event

Image

ESC Congress 2018

25 August - 29 August 2018

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources